Home | Welcome to Contract Pharma   
Last Updated Thursday, October 23 2014
Print RSS Feed

Financial Report: AbbVie



Published July 25, 2014
Related Searches: Biopharma
AbbVie

2Q Revenues: $4.9 billion (+5%)

2Q Earnings: $1.1 billion (+3%)

YTD Revenues: $9.5 billion (+5%)

YTD Earnings: $2.1 billion (+2%)

Comments: Humira sales were up 10% to $3.3 billion in the quarter. AndroGel sales reached $218 million. Synthroid ($166 million), Sevoflurane ($154 million, +11%) and Duodopa ($56 million, +29%) also performed well in the quarter. Kaletra sales dropped 24% to $216 million and Lupron sales were down 3% to $186 million. The company recently announced plans to merge with Shire, creating a larger and more diversified biopharma company with multiple leading franchises.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On